...
首页> 外文期刊>International Journal of Cardiology >Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease
【24h】

Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease

机译:成人先天性心脏病的节段性肺动脉高压的治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) usually has a homogeneous pressure distribution. More rarely, complex CHD patients have segmental PAH. This is often post-surgically. The characteristics of these patients and their responsiveness to specific pulmonary vasodilator therapy have not been described. Methods: Seven adults with segmental PAH complicating CHD were treated at 3 specialized adult CHD centers between January 2006 and December 2010. Clinical characteristics, six minute walking distances (6MWD), laboratory tests and images were obtained from medical records and the responses to Bosentan, an endothelin-1 receptor antagonist, were assessed. Results: All patients (mean age 32 (23-42) years, five females) had a primary diagnosis pulmonary atresia (PA), four with major aortopulmonary collateral arteries (MAPCAs). Four segmental PAH patients had a right pulmonary artery stenosis, two a left pulmonary artery stenosis and one a unilateral MAPCA stenosis. All patients were symptomatic (functional class II or III) and bosentan was started empirically. Bosentan treatment led to a significant improvement in functional class compared to baseline (1.7 ?? 0.5 versus 2.4 ?? 0.5; p < 0.01). Mean 6MWD (available in 6 patients) increased by 62 m (22-150 m) from 386 ?? 135 to 448 ?? 133 m (p = 0.03) after 12 months treatment. Most improvement was seen in patients with low baseline 6MWD. Higher baseline exercise heart rate was significantly associated with lesser improvement in 6MWD (r = - 0.91 p = 0.01). Laboratory results did not change after initiation of bosentan treatment. Conclusion: This small retrospective case series suggested a significant improvement of functional class and exercise capacity after bosentan treatment in patients with segmental PAH. These findings warrant a prospective study of the potential benefit of selective pulmonary vasodilator therapy in these complex patients. Therefore, we call on treating physicians to share similar cases. ? 2011 Elsevier Ireland Ltd.
机译:简介:先天性心脏病(CHD)患者的肺动脉高压(PAH)通常具有均一的压力分布。复杂的冠心病患者很少有节段性PAH。这通常是在手术后进行的。这些患者的特征及其对特定肺血管扩张剂治疗的反应性尚未描述。方法:2006年1月至2010年12月,在3个专门的成人CHD中心对7例成人PAH并发分段性CHD进行了治疗。从医疗记录以及对波生坦的反应中获得临床特征,六分钟步行距离(6MWD),实验室检查和图像,评估内皮素-1受体拮抗剂。结果:所有患者(平均年龄32(23-42)岁,五名女性)均具有初步诊断为肺动脉闭锁(PA),其中四名具有主要的肺门侧副动脉(MAPCA)。 PAH的四节段患者有右肺动脉狭窄,2例左肺动脉狭窄和1例单侧MAPCA狭窄。所有患者都是有症状的(功能性II级或III级),并根据经验开始使用波生坦。与基线相比,波生坦治疗导致功能类别的显着改善(1.7≤0.5 vs 2.4≤0.5; p <0.01)。平均6MWD(6位患者可用)从386 ??增加了62 m(22-150 m)。 135至448 ??治疗12个月后为133 m(p = 0.03)。基线6MWD低的患者最多见改善。较高的基线运动心率与6MWD的改善较少显着相关(r =-0.91 p = 0.01)。开始波生坦治疗后实验室结果未改变。结论:这一小型回顾性病例系列表明,波生坦治疗后的部分PAH患者的功能分类和运动能力有显着改善。这些发现需要对这些复杂患者进行选择性肺血管扩张治疗的潜在益处进行前瞻性研究。因此,我们呼吁治疗医生分享类似的案例。 ? 2011爱思唯尔爱尔兰有限公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号